Literature DB >> 15335318

Treatment and prevention of enterococcal infections--alternative and experimental approaches.

Stefanie Koch1, Markus Hufnagel, Johannes Huebner.   

Abstract

Enterococci are one of the leading types of organisms isolated from infections of hospitalised patients and the third most common cause of nosocomial bloodstream infections. They contribute significantly to patient mortality and morbidity, as well as healthcare costs. The emergence of resistance against virtually all clinically available antibiotics and the ability to transfer these resistance determinants to other pathogens demonstrates the urgency for an improved understanding of enterococcal virulence mechanisms, and the development of alternative treatment and prevention options. This article reviews new antimicrobials, vaccine targets, bacteriophage therapy, as well as treatments targeting virulence factors and biofilm, for their potential to treat and/or prevent enterococcal infections. Although clinical isolates often cause serious infections, so-called 'non-pathogenic' strains are used as therapeutics in the form of probiotics. Understanding the differences between true pathogens and beneficial commensals may help to evaluate future treatment and prophylactic options.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15335318     DOI: 10.1517/14712598.4.9.1519

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  8 in total

1.  Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence.

Authors:  Rebecca L Wilson; Lindsay L Brown; Dana Kirkwood-Watts; Travis K Warren; S Amanda Lund; David S King; Kevin F Jones; Dennis E Hruby
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Toxin-antitoxin systems are ubiquitous and plasmid-encoded in vancomycin-resistant enterococci.

Authors:  Elizabeth M Moritz; Paul J Hergenrother
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

3.  Surface protein EF3314 contributes to virulence properties of Enterococcus faecalis.

Authors:  Roberta Creti; Francesca Fabretti; Stefanie Koch; Johannes Huebner; Danielle A Garsin; Lucilla Baldassarri; Lucio Montanaro; Carla Renata Arciola
Journal:  Int J Artif Organs       Date:  2009-09       Impact factor: 1.595

4.  Role of mprF1 and mprF2 in the pathogenicity of Enterococcus faecalis.

Authors:  Yinyin Bao; Tuerkan Sakinc; Diana Laverde; Dominique Wobser; Abdellah Benachour; Christian Theilacker; Axel Hartke; Johannes Huebner
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

5.  Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci.

Authors:  Ermioni Kalfopoulou; Diana Laverde; Karmela Miklic; Felipe Romero-Saavedra; Suzana Malic; Filippo Carboni; Roberto Adamo; Tihana Lenac Rovis; Stipan Jonjic; Johannes Huebner
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

6.  Conjugation of Different Immunogenic Enterococcal Vaccine Target Antigens Leads to Extended Strain Coverage.

Authors:  F Romero-Saavedra; D Laverde; E Kalfopoulou; C Martini; R Torelli; D Martinez-Matamoros; M Sanguinetti; J Huebner
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

7.  Complete Genome Sequence of Enterococcus Bacteriophage EFLK1.

Authors:  Leron Khalifa; Shunit Coppenhagen-Glazer; Mor Shlezinger; Miriam Kott-Gutkowski; Omri Adini; Nurit Beyth; Ronen Hazan
Journal:  Genome Announc       Date:  2015-11-19

Review 8.  Advances and Prospects in Vaccine Development against Enterococci.

Authors:  Ermioni Kalfopoulou; Johannes Huebner
Journal:  Cells       Date:  2020-11-02       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.